Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 271-784-1 | CAS number: 68608-50-4
Data on the human serum lithium ion concentration are provided in the Repeated Dose Toxicity Endpoint section.
The lithium cation has been used extensively in human therapy for bipolar disease for example, in the form of lithiumsalts (e.g. carbonate, acetate, sulphate). As a result, considerable information is available on safe serum lithium ion concentrations over long periods of administration. Since the fatty acid anion of the lithium fatty acid salts is not considered to be a hazard, it is appropriate to use the human serum lithium ion concentration, converted to equivalent lithium fatty acid concentration, as the DNEL for the lithium salts of monocarboxylic acids C14 -C22 category.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again